How strong is the evidence behind Fish Oil for this claim?

NutriStack rates this as Moderate evidence, meaning several aligned RCTs or one large RCT plus supporting reviews. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

What contrary evidence or caveats apply?

DHA-dominant formulations show little effect. Effect is smaller as a monotherapy in mild depression.

Show your sourcesModerate evidenceReviewed May 2026

Omega-3 fatty acids reduce depressive symptoms, the receipts.

Meta-analyses find a small but real effect, primarily driven by EPA-dominant formulations, especially as an adjunct to standard antidepressant therapy.

3 of 3 matching studies surfaced. NutriStack rating: moderate evidence. Last reviewed May 26, 2026.

How we tier evidence →Browse all claim deep dives

Moderate evidence, per the methodology. Strongest 3 studies linked to PubMed.
Recommendation, contrary evidence, and dose are all on this page.

The studies·Contrary evidence·Recommendation

The studies

Strongest evidence, sourced.

Sorted by study tier (meta-analyses first, then RCTs, then reviews) and recency. Every entry links to PubMed by PMID.

At a glance

Substances: Fish Oil
Evidence tier: Moderate evidence
Strongest studies surfaced: 3 of 3 matching
One-line verdict: Best as an EPA-dominant adjunct.
Last verified: May 30, 2026

Top 3 studies

Meta-analysis Liao Y, Xie B, Zhang H et al., Mol Psychiatry 2019 · n=2,160

Omega-3 polyunsaturated fatty acids for the treatment of depression: systematic review and meta-analysis PMID 31228684

Omega-3 PUFAs had a significant beneficial effect on depression symptoms
Meta-analysis Liao Y, Xie B, Zhang H et al., Translational Psychiatry 2019

Efficacy of omega-3 PUFAs in depression: A meta-analysis. PMID 31383846

Omega-3 PUFA supplementation significantly reduced depressive symptoms, with higher doses of EPA showing greater efficacy.
Meta-analysis Martins JG, J Am Coll Nutr 2009

EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials PMID 20439549

EPA-predominant formulations (>60% EPA) demonstrated clinical benefit in depression, whereas DHA-predominant formulations did not.

Contrary evidence

What pushes back.

Caveats, null findings, and methodological limits that hold the tier where it is.

What argues against the claim

DHA-dominant formulations show little effect.
Effect is smaller as a monotherapy in mild depression.

Recommendation

What the evidence supports.

What we recommend, with caveats

1 to 2 g/day of an EPA-dominant fish oil (EPA:DHA ratio 2:1 or higher) as an adjunct, not a replacement, for depression treatment.

Tier criteria are documented at /methodology/evidence-tiers. Sourcing standards at /methodology/interactions.

Stack interaction risks

Where these substances clash.

Documented pairings involving the substances behind this claim. Cautions and conflicts come first.

Pairs in the database

Open the free interaction checker at /interactions to scan a full routine.

Before you go

One claim, opened up. NutriStack does this for every claim in the database.

The full library lives at /research. Every entry follows the same shape: the verdict, the studies, the contrary evidence, the recommendation, and the primary literature.

Browse all claim deep dives →Read the methodology